GRI Bio Receives FDA Orphan Drug Designation for GRI-0621
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
GRI Bio announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis, a progressive, irreversible and ultimately fatal lung disease affecting tens of thousands of patients in the United States. "Receiving FDA Orphan Drug Designation for GRI-0621 in IPF is an important validation of our development strategy and highlights the urgent need for innovative therapies capable of altering the course of this devastating disease," said Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio. "We believe GRI-0621's differentiated mechanism of action has the potential to address key drivers of inflammation and fibrosis, and this designation strengthens our ability to advance the program efficiently while creating significant long-term value for patients and shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRI
Wall Street analysts forecast GRI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.320
Low
10.00
Averages
23.00
High
36.00
Current: 2.320
Low
10.00
Averages
23.00
High
36.00
No data
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRI Bio Secures Orphan Drug Designation for GRI-0621, Advancing Development
- Regulatory Milestone: GRI Bio announced that its drug GRI-0621 for treating Idiopathic Pulmonary Fibrosis has received Orphan Drug Designation from the FDA, a significant achievement that not only validates the company's development strategy but also highlights the drug's potential to meet significant unmet medical needs.
- Market Exclusivity: With the Orphan Drug Designation, GRI-0621 is poised to gain up to seven years of U.S. market exclusivity upon approval, providing substantial commercialization benefits and enhancing the company's competitive position in the biopharmaceutical market.
- Clinical Trial Success: GRI-0621 successfully met primary and secondary endpoints in a Phase 2 trial involving 35 patients with Idiopathic Pulmonary Fibrosis, demonstrating its potential to improve patient outcomes and further supporting the company's research direction in this area.
- Strategic Commitment: GRI Bio CEO Marc Hertz emphasized the company's commitment to advancing GRI-0621 with urgency, as the Orphan Drug Designation strengthens its regulatory foundation and supports its mission to deliver innovative therapies for severe diseases while laying the groundwork for sustainable long-term growth.
See More
GRI Bio CEO to Participate in Healthcare Showcase
- Executive Participation: GRI Bio's CEO, Dr. Marc Hertz, will participate in A.G.P.'s Annual Healthcare Company Showcase on May 20, 2026, highlighting the company's innovative immune-modulating pipeline, which is expected to attract investor interest.
- Pipeline Progress: The company is advancing NKT cell modulators targeting inflammatory, fibrotic, and autoimmune diseases, particularly GRI-0621, a novel oral therapeutic for idiopathic pulmonary fibrosis, addressing significant unmet needs in the market.
- Technological Innovation: GRI Bio's therapies aim to interrupt disease progression and restore immune homeostasis by targeting NKT cells, demonstrating potential to transform treatment paradigms for complex diseases.
- Future Outlook: With a library of over 500 proprietary compounds, GRI Bio supports its growing pipeline, potentially driving the development of more innovative therapies and enhancing its competitive position in the market.
See More
GRI Biopress Reports Q1 Financial Results
- Reduced Net Loss: GRI Biopress reported a net loss of approximately $2.0 million for Q1 2026, a 33.3% decrease from the $3.0 million loss in the same period of 2025, indicating improvements in cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, GRI Biopress had cash and cash equivalents totaling approximately $11.0 million, reflecting a 34.1% increase from $8.2 million on December 31, 2025, which provides stronger liquidity support for operations.
- Financial Health Indicators: Although still in a loss position, the reduction in net loss and increase in cash reserves suggest improvements in financial health, potentially boosting investor confidence in the company's future prospects.
- Market Outlook: With the gradual improvement in financial conditions, GRI Biopress is likely to attract more investor attention, particularly in light of potential growth opportunities in the biotechnology sector.
See More
Grainger PLC Reports Strong Financial Performance Amid Challenges
- Strong Financial Performance: Grainger PLC reported a 7.8% increase in rental income and a 3.1% like-for-like rental growth, with expectations to achieve £60 million in EPRA earnings this year, reflecting a 12% increase from 2025 and a target of 35% growth by 2029, indicating robust performance in the rental market and future growth potential.
- High Occupancy and Retention Rates: The company maintained a high occupancy rate of 96% and a customer retention rate of 61%, demonstrating strong demand for rental properties, which enhances its competitive position in a challenging market.
- Future Growth Pipeline: Grainger PLC has a committed pipeline of 775 homes that will drive future earnings growth and margin expansion, further solidifying its market leadership.
- Market Challenges and Responses: Despite a 2.7% decrease in EPRA NTA to 290p per share and rising financing costs impacting short-term performance, the company maintains flexibility through an asset disposal strategy, ensuring continued earnings growth even in a high-interest rate environment.
See More
GRI Bio Reports Phase 2a Data for GRI-0621 in IPF
- Clinical Data Highlights: GRI-0621 demonstrated zero cough and approximately 60% reduction in treatment-related diarrhea in the Phase 2a trial for IPF, despite a 67% increase in nintedanib use in the active arm, suggesting GRI-0621 may effectively mitigate nintedanib-related GI toxicities, enhancing its competitive position in the market.
- Pulmonary Function Improvement: The trial showed an overall improvement of 99 mL in FVC at 12 weeks, with a 139 mL improvement in the SOC combination subset, indicating its potential in enhancing lung function and paving the way for future regulatory approvals.
- Strong Financial Position: As of March 31, 2026, GRI Bio reported approximately $11.0 million in cash and cash equivalents, up from $8.2 million at the end of 2025, indicating effective financial management and sufficient resources to support operations into the second quarter of 2027.
- Reduced R&D Expenses: Research and development expenses for Q1 2026 were approximately $0.4 million, significantly down from $1.6 million in the same period of 2025, reflecting the completion of the Phase 2a clinical trial for GRI-0621 and optimized resource allocation.
See More
GRI Bio Reports New Data Advancing NKT Cell Therapy Progress
- Clinical Trial Progress: GRI Bio announced additional positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), revealing significant improvements in key biomarkers, indicating the efficacy of its treatment approach in fibrosis and lung repair, potentially offering new therapeutic options for patients.
- Biomarker Results: The reported biomarker results demonstrate that NKT cell modulators significantly improve drivers of fibrosis, which not only enhances understanding of disease mechanisms but may also propel the development of subsequent treatment regimens.
- Innovative Treatment Pipeline: GRI Bio's lead program, GRI-0621, acts as an RARβγ agonist aimed at inhibiting iNKT cell activity, addressing the significant unmet need in treating IPF, showcasing strong market potential.
- Diversified Drug Development: The company is developing various novel dNKT agonists for conditions like systemic lupus erythematosus, and with a library of over 500 proprietary compounds, GRI Bio is well-positioned to continuously advance its innovative drug pipeline.
See More
GRI Bio Secures Orphan Drug Designation for GRI-0621, Advancing Development
- Regulatory Milestone: GRI Bio announced that its drug GRI-0621 for treating Idiopathic Pulmonary Fibrosis has received Orphan Drug Designation from the FDA, a significant achievement that not only validates the company's development strategy but also highlights the drug's potential to meet significant unmet medical needs.
- Market Exclusivity: With the Orphan Drug Designation, GRI-0621 is poised to gain up to seven years of U.S. market exclusivity upon approval, providing substantial commercialization benefits and enhancing the company's competitive position in the biopharmaceutical market.
- Clinical Trial Success: GRI-0621 successfully met primary and secondary endpoints in a Phase 2 trial involving 35 patients with Idiopathic Pulmonary Fibrosis, demonstrating its potential to improve patient outcomes and further supporting the company's research direction in this area.
- Strategic Commitment: GRI Bio CEO Marc Hertz emphasized the company's commitment to advancing GRI-0621 with urgency, as the Orphan Drug Designation strengthens its regulatory foundation and supports its mission to deliver innovative therapies for severe diseases while laying the groundwork for sustainable long-term growth.
See More
GRI Bio CEO to Participate in Healthcare Showcase
- Executive Participation: GRI Bio's CEO, Dr. Marc Hertz, will participate in A.G.P.'s Annual Healthcare Company Showcase on May 20, 2026, highlighting the company's innovative immune-modulating pipeline, which is expected to attract investor interest.
- Pipeline Progress: The company is advancing NKT cell modulators targeting inflammatory, fibrotic, and autoimmune diseases, particularly GRI-0621, a novel oral therapeutic for idiopathic pulmonary fibrosis, addressing significant unmet needs in the market.
- Technological Innovation: GRI Bio's therapies aim to interrupt disease progression and restore immune homeostasis by targeting NKT cells, demonstrating potential to transform treatment paradigms for complex diseases.
- Future Outlook: With a library of over 500 proprietary compounds, GRI Bio supports its growing pipeline, potentially driving the development of more innovative therapies and enhancing its competitive position in the market.
See More
GRI Biopress Reports Q1 Financial Results
- Reduced Net Loss: GRI Biopress reported a net loss of approximately $2.0 million for Q1 2026, a 33.3% decrease from the $3.0 million loss in the same period of 2025, indicating improvements in cost control and operational efficiency.
- Improved Cash Position: As of March 31, 2026, GRI Biopress had cash and cash equivalents totaling approximately $11.0 million, reflecting a 34.1% increase from $8.2 million on December 31, 2025, which provides stronger liquidity support for operations.
- Financial Health Indicators: Although still in a loss position, the reduction in net loss and increase in cash reserves suggest improvements in financial health, potentially boosting investor confidence in the company's future prospects.
- Market Outlook: With the gradual improvement in financial conditions, GRI Biopress is likely to attract more investor attention, particularly in light of potential growth opportunities in the biotechnology sector.
See More
Grainger PLC Reports Strong Financial Performance Amid Challenges
- Strong Financial Performance: Grainger PLC reported a 7.8% increase in rental income and a 3.1% like-for-like rental growth, with expectations to achieve £60 million in EPRA earnings this year, reflecting a 12% increase from 2025 and a target of 35% growth by 2029, indicating robust performance in the rental market and future growth potential.
- High Occupancy and Retention Rates: The company maintained a high occupancy rate of 96% and a customer retention rate of 61%, demonstrating strong demand for rental properties, which enhances its competitive position in a challenging market.
- Future Growth Pipeline: Grainger PLC has a committed pipeline of 775 homes that will drive future earnings growth and margin expansion, further solidifying its market leadership.
- Market Challenges and Responses: Despite a 2.7% decrease in EPRA NTA to 290p per share and rising financing costs impacting short-term performance, the company maintains flexibility through an asset disposal strategy, ensuring continued earnings growth even in a high-interest rate environment.
See More
GRI Bio Reports Phase 2a Data for GRI-0621 in IPF
- Clinical Data Highlights: GRI-0621 demonstrated zero cough and approximately 60% reduction in treatment-related diarrhea in the Phase 2a trial for IPF, despite a 67% increase in nintedanib use in the active arm, suggesting GRI-0621 may effectively mitigate nintedanib-related GI toxicities, enhancing its competitive position in the market.
- Pulmonary Function Improvement: The trial showed an overall improvement of 99 mL in FVC at 12 weeks, with a 139 mL improvement in the SOC combination subset, indicating its potential in enhancing lung function and paving the way for future regulatory approvals.
- Strong Financial Position: As of March 31, 2026, GRI Bio reported approximately $11.0 million in cash and cash equivalents, up from $8.2 million at the end of 2025, indicating effective financial management and sufficient resources to support operations into the second quarter of 2027.
- Reduced R&D Expenses: Research and development expenses for Q1 2026 were approximately $0.4 million, significantly down from $1.6 million in the same period of 2025, reflecting the completion of the Phase 2a clinical trial for GRI-0621 and optimized resource allocation.
See More
GRI Bio Reports New Data Advancing NKT Cell Therapy Progress
- Clinical Trial Progress: GRI Bio announced additional positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), revealing significant improvements in key biomarkers, indicating the efficacy of its treatment approach in fibrosis and lung repair, potentially offering new therapeutic options for patients.
- Biomarker Results: The reported biomarker results demonstrate that NKT cell modulators significantly improve drivers of fibrosis, which not only enhances understanding of disease mechanisms but may also propel the development of subsequent treatment regimens.
- Innovative Treatment Pipeline: GRI Bio's lead program, GRI-0621, acts as an RARβγ agonist aimed at inhibiting iNKT cell activity, addressing the significant unmet need in treating IPF, showcasing strong market potential.
- Diversified Drug Development: The company is developing various novel dNKT agonists for conditions like systemic lupus erythematosus, and with a library of over 500 proprietary compounds, GRI Bio is well-positioned to continuously advance its innovative drug pipeline.
See More
